Herantis Pharma has announced that patient visits have been completed for the final cohort from its Phase Ib trial evaluating lead candidate HER-096 in Parkinson’s disease (PD). The primary objective of the study is to confirm that repeated subcutaneous doses of HER-096 are safe and well tolerated.
